One of the most dreaded feelings for an investor is when the stock they just bought is overvalued, or they missed out on an undervalued opportunity by not acting fast enough.

But what if you had the insights to effectively evaluate a company like Revance Therapeutics Inc before investing? Investing requires a certain perspective to avoid being overly confident in a company or worried about cyclical changes. A smart way to take the guesswork out of knowing when to buy or sell Revance Therapeutics Inc’s stock is to have the right tools and resources as well as a clear monitoring process.

In this article, we go over a few key elements for understanding Revance Therapeutics Inc’s stock price such as:

• Current stock price and volume
• Stock price history
• Upgrades and downgrades from analysts
• Stock price momentum as measured by its relative strength

About Revance Therapeutics Inc (RVNC)

Before we jump into Revance Therapeutics Inc’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Revance Therapeutics, Inc. is a biotechnology company. The Company is focused on advanced aesthetic and therapeutic offerings. The Company?s aesthetics portfolio of expertly created products and services, including DAXXIFY (DaxibotulinumtoxinA-lanm) for injection, the RHA Collection of dermal fillers, and OPUL, the first-of-its-kind relational commerce platform for aesthetic practices. The Company?s therapeutics pipeline is focused on muscle movement disorders, including evaluating DAXXIFY in two debilitating conditions, cervical dystonia and upper limb spasticity. The DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient along with the other excipients. DAXXIFY a commercially approved product, is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.

Want to learn more about Revance Therapeutics Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Revance Therapeutics Inc. The AAII Stock Evaluator puts a company’s grades, charts, news, financials, valuation, ratios, filings and more at your fingertips.

Revance Therapeutics Inc’s Stock Price as of Market Close

As of September 08, 2023, 4:00 PM CST, Revance Therapeutics Inc’s stock price was $15.49.

Revance Therapeutics Inc is down 6.57% from its previous closing price of $16.58.

During the last market session, Revance Therapeutics Inc’s stock traded between $16.14 and $16.81. Currently, there are 83.69 million shares of Revance Therapeutics Inc stock available for purchase.

Unfortunately, Revance Therapeutics Inc’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Revance Therapeutics Inc Stock Price History

Revance Therapeutics Inc’s (RVNC) price is currently down 12.14% so far this month.

During the month of September, Revance Therapeutics Inc’s stock price has reached a high of $18.34 and a low of $15.47.

Over the last year, Revance Therapeutics Inc has hit prices as high as $37.98 and as low as $16.14. Year to date, Revance Therapeutics Inc’s stock is down 5.09%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Revance Therapeutics Inc Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 07, 2023, there were 4 analysts who downgraded Revance Therapeutics Inc’s stock and 4 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Revance Therapeutics Inc’s financial health and valuation. It is possible for a stock to appear cheap based on one valuation metric but appear expensive on another. It is also possible for one valuation ratio to be associated with outperforming stocks during certain periods of time but not others.

Therefore, AAII developed a composite valuation to help resolve such issues. AAII’s Value Grade analyzes six distinct variables: price-to-sales (P/S) ratio, price-earnings (P/E) ratio, the ratio of enterprise value to earnings before interest, taxes, depreciation and amortization (EV/EBITDA), shareholder yield, price-to-book-value (P/B) ratio and price-to-free-cash-flow (P/FCF) ratio.

Revance Therapeutics Inc’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Revance Therapeutics Inc (RVNC) by visiting AAII Stock Evaluator.

Relative Price Strength of Revance Therapeutics Inc

Relative price strength addresses the relationship between a stock price’s trend and the price trend of the market. This ratio is expressed as a percentage and helps investors understand a company’s momentum as well as its value. You can use relative price strength to select investments that have been outperforming the market or a specific benchmark.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. The weighted four-quarter relative price strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40%, and each of the three previous quarters are given a weighting of 20%.

As of September 07, 2023, Revance Therapeutics Inc has a weighted four-quarter relative price strength of -11.36%, which translates to a Momentum Score of 30 and is considered to be Weak.

Want to learn more about how Revance Therapeutics Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Revance Therapeutics Inc Stock Price: Bottom Line

As of September 8, 2023, Revance Therapeutics Inc’s stock price is $15.49, which is down 6.57% from its previous closing price.

At AAII, we stress that investors should never buy or sell a stock solely based on its stock price. Past returns do not guarantee future performance. Therefore, you should consider multiple ratios, fundamentals and analytics before making a decision. Whether you decide it’s a good time to buy or sell Revance Therapeutics Inc’s stock based on its stock price forecast is ultimately up to you.

It’s important to understand that stock prices are driven by a variety of factors, but ultimately the price at any given moment is due to the supply and demand in the market. Stock price overviews, like the one you just read, only give you a small snapshot of a company’s performance, value and momentum.

By becoming an A+ Investor subscriber, you will have full access to analytics, grades, stock screens, commentary and more so you can invest with confidence.